

Retrospective study of metronomic chemotherapy in advanced NSCLC at a tertiary centre in south India

Shobitha Rao¹ and Guruprasad B. ^{*2}

¹Department of Respiratory Medicine, Srinivas Institute of Medical Sciences and Research Centre Mangalore, India

²Department of Medical Oncology, Yenepoya Medical College Mangalore, India

Abstract

Background: Chemotherapy and immunotherapy are the backbone for treatment of most NSCLC (non small cell lung cancer). But many patients are not able to tolerate chemotherapy and not able to afford immunotherapy in our scenario.

Objective: The aim of this retrospective study was to assess the clinical activity and toxicity profile of metronomic therapy with cyclophosphamide and etoposide in advanced NSCLC.

Material and methods: Fifty patients were treated (20 treatment naive patients, 10 as second line therapy and 20 as maintenance therapy) between Feb 2015 and Feb 2018. Patients were given tab cyclophosphamide 50 mg once daily and Cap. Etoposide 50 mg alternate days continuously till disease progression. Patients were assessed for treatment response in the form of progression free survival.

Results: The median age was 65 years. The median duration of treatment was 6 months. Response was seen in form of stable disease only, in 16 patients. Median progression free survival was 4 months in treatment naive, 7 months in setting of maintenance therapy and 3 months in second line setting.

Conclusion: In resource limited setting, metronomic chemotherapy is useful in advanced NSCLC. This is an affordable regimen which has minimal toxicity with promising survival.

Keywords: NSCLC, metronomic therapy

*Correspondence Info:

Dr. Guruprasad B.
Assistant Professor,
Department of Medical Oncology,
Yenepoya Medical College Mangalore, India

*Article History:

Received: 26/11/2018
Revised: 09/01/2019
Accepted: 09/01/2018
DOI: <https://doi.org/10.7439/ijbr.v10i1.4976>

QR Code



How to cite: Rao S, Bhat G. Retrospective study of metronomic chemotherapy in advanced NSCLC at a tertiary centre in south India. *International Journal of Biomedical Research* 2019; 10(01): e4976. doi: 10.7439/ijbr.v10i1.4976 Available from: <https://ssjournals.com/index.php/ijbr/article/view/4976>

Copyright (c) 2019 International Journal of Biomedical Research. This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/)

1. Introduction

Lung cancer is the leading cause of cancer mortality worldwide [1]. Nearly 70% are diagnosed with advanced disease at presentation [2]. Approximately 85% of lung cancers are NSCLC (non small cell lung cancer). Intravenous chemotherapy and immunotherapy are now the standard treatment regimes for advanced NSCLC. The problem with intravenous chemotherapy is that many elderly patients do not tolerate platinum doublet and immunotherapy is too expensive for most patients. Hence the need for non toxic, affordable regimen arises. Metronomic chemotherapy has been studied extensively in multiple cancers; however studies in lung cancer are lacking [3].

Our study aimed to study the effect of metronomic therapy in advanced lung cancer patients.

2. Materials and methods

This retrospective study was done at the department of medical oncology, Yenepoya medical college Mangalore. Data of cases of advanced NSCLC on metronomic chemotherapy during a period of three years from Feb 2015 to Feb 2018 was collected from the medical case records. Histologically confirmed cases of advanced NSCLC on metronomic chemotherapy, over the age of 18 years of either gender were included. The age, sex, epidermal growth factor receptor (EGFR) status, anaplastic lymphoma kinase (ALK) status, co morbidities, eastern cooperative oncology group performance status (ECOG PS), number of metastatic sites and whether treatment was in first line setting or maintenance therapy or recurrent setting was noted. Metronomic chemotherapy consisted of combination of tablet cyclophosphamide 50 mg given once

daily with Capsule Etoposide 50 mg given on alternate days continuously till disease progression. A semi-structured Performa was used to collect information from the medical case records. Records were checked for any evidence of toxicity and response to the treatment regimen. Patients were assessed for treatment response in the form of progression free survival and also assessed for drug toxicities.

2.1 Statistical analysis

Data was entered in Microsoft Office Excel worksheet and analyzed using statistical software SPSS version 17.0. For qualitative data, Chi square test was used and P value <0.05 considered statistically significant.

3. Results

Case records of NSCLC patients admitted during a period of Feb 2015 to Feb 2018 revealed that 50 cases were eligible for this study after satisfying the inclusion and exclusion criteria. Of these twenty patients were treatment naive, ten patients were treated as second line therapy and twenty patients received metronomic therapy as maintenance therapy. The patient characteristics are shown in Table 1. The median age of study population was 65 years (range 51-82 years). Majority of the study population were males (40 out of 50). Adenocarcinoma and squamous cancer accounted for 64% and 20% respectively. EGFR testing was done in 12 patients and 5 patients (nearly 41%) were positive, these patients received first line tyrosine kinase inhibitors and on progression received metronomic therapy. ALK testing was done in 5 patients all of them were negative.

3.1 Survival

The median duration of treatment was 6 months. Response was seen in form of stable disease only, in 16 patients. Median progression free survival was 4 months in treatment naive, 7 months in setting of maintenance therapy and 3 months in second line setting (Figure 1).

3.2 Toxicities

The median number of months of treatment for all patients was 5 months (Range 1-24 months). The most common toxicities were hematologic. 6 patients developed neutropenia (Grade 1-2 in 5 patients and Grade 3-4 in one patient). No treatment discontinuation was seen due to toxicity; no treatment-related death was reported.

4. Discussion

This study assessed the clinical efficacy and toxicity of metronomic therapy in patients with advanced NSCLC. The use of standard chemotherapy in elderly lung cancer patients is associated with significant toxicities resulting in poor quality of life. Metronomic chemotherapy works by antiangiogenic mechanism. These regimens usually use lower dose of chemotherapy agents, lower than their maximal tolerable dose [4].


Different regimens of metronomic therapy have been tried in lung cancer. These include drugs like etoposide, cyclophosphamide, vinorelbine and paclitaxel [5]. Metronomic paclitaxel is associated with significant anemia (8%) neutropenia (5.4%) and sensory neuropathy (5.4%)[6]. Metronomic vinorelbine is associated with significant anemia (44%), fatigue (32%) and diarrhea (10.5%) [7]. These are not seen with the above regimen. Compared to other regimens which are intravenous, this regimen has less frequent admission, lesser side effects making it desirable for elderly patients who have to travel long distance for health care facility and being very affordable[4].

There are several studies looking at survival with metronomic therapy. Most studies have compared it in first line and second line setting, resulting in a progression free survival of 3-6 months [8],[9]. We also looked at role this combination in maintenance regimen. Compared to other regimens, this had better results than most single agent (4.8 months in FLEX study, 4.4 months in PARAMOUNT study)[12],[13] but inferior survival than combination maintenance regimen like bevacizumab with pemetrexate (10.2 months PFS in AVAPERL study and 12.8 months PFS in POINTBREAK study)[10],[11].

Metronomic chemotherapy is not a standard treatment protocol for lung cancer patients due to lack of prospective randomised clinical trials. In resource limited setting, metronomic chemotherapy is useful in advanced NSCLC. This is an affordable regimen which has minimal toxicity with promising survival.

Table 1: Patient characteristics

	Number of patients
Age:	Median
Sex	
Male	40
female	10
EGFR status	
Not known	38(76%)
Test done in (positivity)	12(41%)
ALK status	
Test done in (positivity)	5(0%)
Performance status	
PS:0-1	41(82%)
PS: 2 and above	9(18%)
Line of therapy	
First line	20(40%)
Maintenance setting	20(40%)
Recurrent setting	10(20%)
Smokers	35(70%)
Histology	
Squamous	10(20%)
Adenocarcinoma	32(64%)
Poorly differentiated cancer	8(16%)

Figure 1: Survival with metronomic therapy

References

- [1]. Global Burden of Disease Cancer Collaboration , Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H *et al*. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. *JAMA Oncol* 2017; 3:524-48.
- [2]. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. *J Thorac Oncol*. 2010 Jan; 5(1): 29-33.
- [3]. Noronha V, Krishna MV, Patil V, Joshi A, Banavali SD, Prabhash K. Metronomic therapy: Chemotherapy revisited. *Indian J Cancer* 2013 Apr-Jun; 50(2):142-8.
- [4]. Grunberg, S.M. Cyclophosphamide and etoposide for non-small cell and small cell lung cancer. *Drugs*. 1999 Nov; 58(3): 11-15.
- [5]. Kosmidis PA, Syrigos K, Kalofonos HP, Dimopoulos MA, Skarlos D, Pavlidis N, Boukovinas I, Bafaloukos D, Pectasides D, Bacoyiannis C, Fountzilas G. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2. *Anticancer Res*. 2012 Jan; 32(1):175-81.
- [6]. Noronha V, Patil VM, Joshi A, Prabhash K. Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer. *Indian J Cancer* 2013 Apr-Jun; 50(2):122-7.
- [7]. Camerini A, Puccetti C, Donati S, Valsuani C, Petrella MC, Tartarelli G, Puccinelli P, Amoroso D. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). *BMC Cancer* 2015 May 6; 15:359.
- [8]. BJ S., Lalkota B. P., Veldhore V. H., Rao R., Naik R. Efficacy study of metronomic chemotherapy in metastatic NSCLC and correlation with VEGF and Thrombospondin levels. *WCRJ* 2017; 4 (2): e878.
- [9]. Kosmidis PA, Syrigos K, Kalofonos HP, Dimopoulos MA, Skarlos D, Pavlidis N, Boukovinas I, Bafaloukos D, Pectasides D, Bacoyiannis C, Fountzilas G. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2. *Anticancer Res*. 2012 Jan; 32(1):175-81.
- [10]. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). *J Clin Oncol* 2013 Aug 20; 31(24):3004-11.
- [11]. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Møller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. Point Break: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. *J Clin Oncol*. 2013 Dec 1; 31(34): 4349-57.
- [12]. Pirker R., Pereira J., Szczesna A., Von Pawel J., Krzakowski M., Ramlau R., *et al*. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet* 2009; 373: 1525–1531
- [13]. Paz-Ares LG, de Marinis F, Dedi M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol*. 2013 Aug 10; 31(23): 2895-902.